BREAK THROUGH CANCER

HRA Members Meeting
Recent Innovations in Research Funding Mechanisms
March 21, 2023

Break Through Cancer **empowers outstanding researchers and physicians** to both intercept and find cures for some of the **deadliest cancers** by stimulating **radical collaboration.**

Break Through Cancer Model: TeamLabs

Guided and empowered by three principles of **radical collaboration:**

1. Commitment to real-time sharing of data and discovery
2. Trust in colleagues and willingness to offer and receive criticism of each other's ideas
3. Urgent focus on discoveries and their translation to advance science and patient care



Defining Principles



Act urgently

Taking a patient-focused perspective

Be bold

Pursuing new technologies and "outsider" perspectives

Eliminate barriers

Solving structural challenges impeding science

Act equitably

Ensuring patients and research teams are inclusive

Create Lasting Relationships

Creating shared culture to build trust and align incentives

Key Goals

1. Revolutionize cancer interception at national scale
2. Accelerate the pace of drug approval by learning from patients
3. Incentivize radical collaboration between researchers in academia and industry

Mission Coalescing around Strategic Concepts

- Iterating quickly between the lab and the clinic bring the **worlds of preclinical and clinical research** closer than ever before
- Demonstrating scientific value of **therapeutic intervention at time of minimal residual disease**
- Making **early cancer interception** (detection, drugs, vaccination) possible and impactful for patients, in an equitable manner
- Harnessing new technologies to help **make new types of first in human "signal finding" therapeutic studies possible**
- Demonstrating the **impact of new partnership models to accelerate research to benefit patients, faster**
- Creating paths to ultimately **influence policymakers and payers to adopt new standards**

Iterative Project Development Process

Brainstorming

Moderated discussions with institutional experts around unique scientific opportunity

Visioning



Articulate problem statements into a 1-page call to action; early engagement with SAB

Prioritization

Team(s) and project formation to address problem statements, (development of proposal, budgets, timeline, metrics of success)

Selection



SAB reviews; CSO recommends; Board approves

Launch

Projects launch! Break Through Cancer Program and Data Managers deployed

Execution/ Iteration



Close partnership with BTC and SAB throughout to stay on timeline, problem-solve, pivot, and optimize impact

Initial Projects

KRAS in Pancreatic Cancer
$15M over 3 years—partnership with Lustgarten Foundation
Bring TeamLab and industry partners together to use new technologies to systematically dissect mechanisms of sensitivity and resistance to KRAS drugs in organoids, mice, and humans.



Targeting Clonal Hematopoiesis to Prevent AML
$10M over 3 years
Recruit diverse patients, create new tools, develop drug/vaccine strategies to intercepting progression of CHIP.

Data Science Hub
$25M over 5 years
Invest in data science methods and infrastructure to support multi-institutional, real-time collaboration and develop the next generation of data scientists.



Intercepting Ovarian Cancer
$10.5M over 3 years
Initiate a public health campaign for opportunistic salpingectomy; use single-cell and engineering approaches to map biology of earliest lesions (STICs) and shift standard pathology practices.

Investigating Longitudinal Sampling in Glioblastoma
$12.5M over 3 years
Make intracranial and CSF longitudinal sampling the norm for evaluating all new therapeutics for GBM.

Demystifying Pancreatic Cancer Therapies
$5M over 3 years—collaboration with Lustgarten Foundation
Establish a platform to characterize patient samples from neoadjuvant testing trials, showcasing the power of spatial profiling in the clinic to map biology and immunology.



Targeting Ovarian Cancer MRD Using Immune and DNA Repair Directed Therapies
$15M over 3 years
Understand and treat minimal residual disease through a combination of preclinical and clinical trial approaches.



Identifying, Understanding, and Eradicating MRD in Patients with AML
$10M over 3 years
Explore the biological mechanisms underlying residual AML, seeking to identify targets for treatment strategies that will keep the disease from returning.

BREAK THROUGH CANCER


#RadicalCollaboration